PTD - Peptech US Anti-TNF
12 September 2002
Part 1/1
--------
PEPTECH LIMITED
---------------
HOMEX - Sydney
-------------------------
Peptech US Anti-TNF Patent to be Issued
Peptech today announced that it has received official confirmation
from the US Patent and Trademark Office that patent application
number 9/736,792 will be issued on 17 September 2002 under patent
number 6,451,983 entitled "Tumour Necrosis Factor Antibodies".
Peptech is already receiving royalties from sales of REMICADE (R) in
Australia, Canada, France, Germany, Italy, Switzerland and the United
Kingdom. The next significant milestone for Peptech is the receipt of
th royalties from sales of this anti TNF antibody product in the US.
"Upon review of our patent portfolio, we are extremely confident that
as a result of the issuance of the aforementioned patent, we can now
commence receiving royalties on the sales of REMICADE (R) in the US,
which is by far its largest market. Accordingly, our royalty income
stream will be substantially enhanced although this will not affect
the anticipated loss for our current financial year ending 30
September 2002. Barring unforeseen circumstances, the financial
results commencing from the next financial year will be profitable
ones," said Peptech Managing Director, Stephen Kwik.
Mr Kwik added about today's announcement, "This is a very significant
developmet for the Company. It will enable Peptech to make concrete
plans to grow our earnings by expanding our product pipeline,
developing the lead products from the collaborative work with
Domantis and those from our own internal research work undertaken in
Sydney".
- Forums
- ASX - By Stock
- PATENTS: COUNTDOWN
PTD
unknown
PTD - Peptech US Anti-TNF 12 September 2002Part...
Featured News
Add PTD (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online